keyword
MENU ▼
Read by QxMD icon Read
search

fluticasone

keyword
https://www.readbyqxmd.com/read/29675754/influence-of-mp-29-02-on-ciliary-beat-frequency-in-human-epithelial-cells-in-vitro
#1
D Häussler, J U Sommer, A Nastev, C Aderhold, A Wenzel, B Kramer, B A Stuck, R Birk
PURPOSE: MP 29-02, which contains fluticasone propionate and azelastine hydrochloride, is used as a topical nasal application for the treatment of seasonal and perennial allergic rhinitis. Although a multitude of data is available on the clinical symptom reduction and treatment safety of MP 29-02, the effect of MP 29-02 on ciliary beat frequency (CBF) has not been evaluated thus far. METHODS: MP 29-02-containing solution was applied at concentrations of 2.5, 5, 10, and 20% to 14 healthy subjects, and nasal ciliated epithelial cells were then visualized using a phase-contrast microscope...
April 19, 2018: European Archives of Oto-rhino-laryngology
https://www.readbyqxmd.com/read/29670344/cost-effectiveness-analysis-of-a-fixed-dose-combination-of-indacaterol-and-glycopyrronium-as-maintenance-treatment-for-copd
#2
Ming-Cheng Chan, Elise Chia-Hui Tan, Ming-Chin Yang
Objective: The aim of this study was to evaluate the cost-effectiveness of the long-acting beta-2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) dual bronchodilator indacaterol/glycopyrronium (IND/GLY) as a maintenance treatment for COPD patients from the perspective of health care payer in Taiwan. Patients and methods: We adopted a patient-level simulation model, which included a cohort of COPD patients aged ≥40 years. The intervention used in the study was the treatment using IND/GLY, and comparators were tiotropium or salmeterol/fluticasone combination (SFC)...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29668352/once-daily-single-inhaler-triple-versus-dual-therapy-in-patients-with-copd
#3
David A Lipson, Frank Barnhart, Noushin Brealey, Jean Brooks, Gerard J Criner, Nicola C Day, Mark T Dransfield, David M G Halpin, MeiLan K Han, C Elaine Jones, Sally Kilbride, Peter Lange, David A Lomas, Fernando J Martinez, Dave Singh, Maggie Tabberer, Robert A Wise, Steven J Pascoe
Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2 -agonist (LABA), as compared with dual therapy (either inhaled glucocorticoid-LABA or LAMA-LABA), are uncertain. Methods In this randomized trial involving 10,355 patients with COPD, we compared 52 weeks of a once-daily combination of fluticasone furoate (an inhaled glucocorticoid) at a dose of 100 μg, umeclidinium (a LAMA) at a dose of 62...
April 18, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29667746/an-integrative-approach-combining-passive-sampling-bioassays-and-effect-directed-analysis-to-assess-the-impact-of-wastewater-effluent
#4
Manoj Sonavane, Jennifer E Schollée, Anita O Hidasi, Nicolas Creusot, François Brion, Marc J-F Suter, Juliane Hollender, Selim Aït-Aïssa
Wastewater treatment plant (WWTP) effluents are major sources of endocrine disrupting chemicals (EDCs) and of other chemicals of toxicological concern for the aquatic environment. In this study, we used an integrated strategy combining passive sampling (Chemcatcher®), developmental toxicity and mechanism-based in vitro and in vivo bioassays to monitor the impacts of a WWTP on a river. In vitro screening revealed the WWTP effluent as a source of estrogen (ER), glucocorticoid (GR), aryl hydrocarbon (AhR) receptor mediated activities, impacting the downstream river site where significant activities were also measured, albeit to a lesser extent than in the effluent...
April 18, 2018: Environmental Toxicology and Chemistry
https://www.readbyqxmd.com/read/29650761/once-daily-triple-therapy-inhaler-for-copd
#5
(no author information available yet)
▼Trelegy Ellipta (GSK) is a dry powder inhaler containing fluticasone furoate (inhaled corticosteroid [ICS]), vilanterol trifenatate (long-acting beta2 agonist [LABA]) and umeclidinium bromide (long-acting muscarinic antagonist [LAMA]).1 It is licensed for once-daily use as maintenance treatment for adults with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA. Here, we consider the evidence for this combination product and discuss how it fits with current management strategies...
April 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29648484/serum-periostin-levels-serve-as-a-biomarker-for-both-eosinophilic-airway-inflammation-and-fixed-airflow-limitation-in-well-controlled-asthmatics
#6
Kentaro Takahashi, Kazuyuki Meguro, Hirotoshi Kawashima, Daisuke Kashiwakuma, Shin-Ichiro Kagami, Shoichiro Ohta, Junya Ono, Kenji Izuhara, Itsuo Iwamoto
OBJECTIVE: Periostin, a matricellular protein, is produced from airway epithelial cells and lung fibroblasts by IL-13. It has been suggested that periostin is involved in allergic inflammation and fibrosis. However, the usefulness of serum periostin measurement in the assessment of airway inflammation and remodeling and management of asthmatic patients is still debated. We aimed to determine whether serum periostin levels reflect eosinophilic airway inflammation and airway remodeling in asthma...
April 12, 2018: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/29627483/effects-of-fluticasone-propionate-and-budesonide-on-the-expression-of-immune-defense-genes-in-bronchial-epithelial-cells
#7
M van den Berge, M R Jonker, A Miller-Larsson, D S Postma, I H Heijink
BACKGROUND: COPD patients have increased risk of pneumonia when treated with fluticasone propionate (FP), whereas this is generally not the case with budesonide (BUD) treatment. We hypothesized that BUD and FP differentially affect the expression of immune defense genes. METHODS: Human bronchial epithelial 16HBE cells and air-liquid interface (ALI)-cultured primary bronchial epithelial cells (PBECs) were pre-treated with clinically equipotent concentrations of BUD or FP (0...
April 5, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29583021/copd-2017-a-year-in-review
#8
Ernesto Crisafulli, Antoni Torres
In this review, we focused on original manuscripts published in the 2017 that provided additional information on the clinical and therapeutic features of the chronic obstructive pulmonary disease (COPD). We have chosen eight of these studies, collected in four topics concerning the pharmacological treatment (tiotropium) of mild-moderate patients, the pharmacological (fluticasone furoate/vilanterol/umeclidinium) and non-pharmacological treatment (non-invasive mechanical ventilation) of severe patients, the etiology of acute exacerbation of COPD involving seasonal airway pathogens and the role of eosinophils with particular interest to the monoclonal antibody directed against interleukin-5 (mepolizumab)...
March 27, 2018: COPD
https://www.readbyqxmd.com/read/29582249/fluticasone-propionate-salmeterol-mdpi-airduo-respiclick-%C3%A2-a-review-in-asthma
#9
Julia Paik, Lesley J Scott, Roy A Pleasants
The novel, easy-to-use, breath-actuated fluticasone propionate/salmeterol multidose dry powder inhaler (MDPI) (AirDuo RespiClick® ) was recently approved in the USA for twice-daily treatment of asthma in patients aged ≥ 12 years. This inhaled corticosteroid (ICS) and long-acting β2 -adrenoreceptor agonist (LABA) combination treatment is available in low-, mid- and high-dosage formulations (55/14, 113/14 and 232/14 μg, respectively). In 12-week, phase III trials in patients aged ≥ 12 years with persistent asthma, all three dosages of fluticasone propionate/salmeterol MDPI treatment produced significant improvements in lung function and other asthma symptoms compared with fluticasone propionate MDPI monotherapy or placebo MDPI...
March 26, 2018: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29577787/clinical-and-economic-outcomes-associated-with-the-use-of-fluticasone-propionate-250-mcg-and-salmeterol-50-mcg-combination-versus-tiotropium-bromide-18-mcg-as-initial-maintenance-treatment-for-chronic-obstructive-pulmonary-disease-in-managed-care
#10
Christopher F Bell, Anna D Coutinho, Eileen Farrelly, Tasneem Lokhandwala, Pamela Landsman-Blumberg
AIMS: To examine the clinical and economic outcomes associated with the use of long-acting bronchodilators for initial maintenance treatment of chronic obstructive pulmonary disease (COPD) by analyzing health insurance claims data in the United States. METHODS: A retrospective, observational, matched cohort study used health insurance claims data (January 2008 to June 2013) to assess COPD-related outcomes for subjects aged ≥40 years. Subjects were assigned to a study cohort according to the first observed prescription fill for a long-acting bronchodilator (fluticasone propionate 250 mcg/salmeterol 50 mcg [FSC] or tiotropium bromide 18 mcg [TIO])...
March 24, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29553112/-evaluations-of-sensory-attribute-of-intranasal-corticosteroid-sprays-in-healthy-volunteers
#11
Tetsuo Watanabe, Masashi Suzuki
BACKGROUND: Intranasal corticosteroid sprays (INCSs) have not been a mainstay of the treatment for nasal allergies. We evaluated the sensory effects of INCSs since they might affect compliance to treatment. METHODS: The study population included 45 healthy volunteers. The subjects were randomized 1 : 1 to receive fluticasone furoate (FF) followed by mometasone furoate (MF) or MF followed by FF. There was a 30-minutes waiting period between the administration of each drug...
2018: Arerugī, [Allergy]
https://www.readbyqxmd.com/read/29552322/effect-of-the-asthma-chronic-obstructive-pulmonary-disease-syndrome-on-the-stroke-parkinson-s-disease-and-dementia-a-national-cohort-study
#12
Jun-Jun Yeh, Yu-Feng Wei, Cheng-Li Lin, Wu-Huei Hsu
Background: To evaluate the association of asthma-chronic obstructive pulmonary disease syndrome (ACOS) with neurodegenerative diseases (stroke, Parkinson's disease and dementia) and the role of the steroids in the neurodegenerative diseases among the ACOS cohort. Materials and Methods: Comparison of the ACOS cohort ( N = 10,260) with the non-ACOS cohort ( n = 20,513) based on the patients aged ≧40 years in the National Health Insurance Research Database from January 1, 2000 to December 31, 2010...
February 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29549437/treatment-of-eosinophilic-esophagitis-in-the-pediatric-patient-an-evidence-based-approach
#13
REVIEW
Mery Munoz-Persy, Alfredo J Lucendo
Eosinophilic esophagitis (EoE) is a unique form of non-IgE-mediated food allergy characterized by esophageal eosinophilic infiltration that commonly causes dysphagia and food impaction in children and adolescents. Assessing the efficacy of dietary restrictions or drug therapies to achieve clinical and histologic resolution of EoE through randomized controlled trials and meta-analyses has resulted in new evidence-based guidelines. Avoiding food triggers is the only therapy targeting the cause of the disease...
March 17, 2018: European Journal of Pediatrics
https://www.readbyqxmd.com/read/29546433/cost-effectiveness-of-indacaterol-glycopyrronium-in-comparison-with-salmeterol-fluticasone-combination-for-patients-with-moderate-to-severe-chronic-obstructive-pulmonary-disease-a-lantern-population-analysis-from-singapore
#14
Augustine Tee, Wai Leng Chow, Colin Burke, Guruprasad Basavarajaiah
INTRODUCTION: In light of the growing evidence base for better clinical results with the use of the dual bronchodilator indacaterol/glycopyrronium (IND/GLY) over inhaled corticosteroid-containing salmeterol/fluticasone combination (SFC), this study aimed to evaluate the cost-effectiveness of IND/GLY over SFC in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are at low risk of exacerbations in the Singapore healthcare setting. METHODS: A previously published patient-level simulation model was adapted for use in Singapore by applying local unit costs...
March 16, 2018: Singapore Medical Journal
https://www.readbyqxmd.com/read/29545018/-persistence-to-treatment-and-resources-use-with-inhaled-fixed-dose-combinations-of-corticosteroids-and-long-acting-%C3%AE-adrenergic-agonists-for-the-treatment-of-asthma-a-population-based-retrospective-study
#15
A Sicras-Mainar, S Traseira-Lugilde, T Fernández-Sánchez, R Navarro-Artieda
OBJECTIVE: To determine the persistence, exacerbations, and use of resources in patients who use inhaler treatment with fluticasone propionate/formoterol (PF/Form) in relation with other combinations of inhaled corticosteroid/long-acting β-adrenergic (ICS/LABA) at fixed doses, for the treatment of asthma in real-life practice. MATERIAL AND METHODS: Observational study conducted by reviewing medical records. The study included subjects ≥18 years of age who started treatment with ICS/LABA and who met certain inclusion/exclusion criteria...
March 12, 2018: Semergen
https://www.readbyqxmd.com/read/29537340/single-inhaler-triple-therapy-utilizing-the-once-daily-combination-of-fluticasone-furoate-umeclidinium-and-vilanterol-in-the-management-of-copd-the-current-evidence-base-and-future-prospects
#16
Mario Malerba, Matteo Nardin, Giuseppe Santini, Nadia Mores, Alessandro Radaeli, Paolo Montuschi
Maintenance pharmacological treatment for stable chronic obstructive pulmonary disease (COPD) is based on inhaled drugs, including long-acting muscarinic receptor antagonists (LAMA), long-acting β2 -adrenoceptor agonists (LABA) and inhaled corticosteroids (ICS). Inhaled pharmacological treatment can improve patients' daily symptoms and reduce decline of pulmonary function and acute exacerbation rate. Treatment with all three inhaled drug classes is reserved for selected, more severe, patients with COPD when symptoms are not sufficiently controlled by dual LABA/LAMA therapy and exacerbations are frequent...
January 2018: Therapeutic Advances in Respiratory Disease
https://www.readbyqxmd.com/read/29512364/glucocorticoid-receptor-nuclear-translocation-in-cd4-t-cells-from-severe-and-moderate-asthmatic-patients-treated-with-fluticasone-vilanterol
#17
Zahra Alizadeh, Marzieh Mazinani, Esmaeil Mortaz, Mohammad Reza Fazlollahi, Ian Adcock, Mostafa Moein
Different phenotypes of asthma from mild to severe are categorized based on diverse clinical features. A guideline for the recognition and treatment of asthma has been provided by Global Initiative for Asthma (GINA). To control symptoms and prevent asthma exacerbation in most patients combinational therapy with inhaled corticosteroids (ICS) and a long acting B2-adrenreceptor agonist (LABA) are recommended. Understanding asthma phenotypes would be helpful to improve asthma diagnosis and treatment. The aim of this study was to verify glucocorticoid receptor glcococorticoid receptor (GR) nuclear translocation in CD4 T cells treated with fluticasone furoate (FF), vilanterol (V) and FF/V combination in severe asthmatic patients compare to patients with moderate asthma and healthy controls using Immunocytochemistry (ICC)...
February 2018: Iranian Journal of Allergy, Asthma, and Immunology
https://www.readbyqxmd.com/read/29504498/quintupling-inhaled-glucocorticoids-to-prevent-childhood-asthma-exacerbations
#18
Daniel J Jackson, Leonard B Bacharier, David T Mauger, Susan Boehmer, Avraham Beigelman, James F Chmiel, Anne M Fitzpatrick, Jonathan M Gaffin, Wayne J Morgan, Stephen P Peters, Wanda Phipatanakul, William J Sheehan, Michael D Cabana, Fernando Holguin, Fernando D Martinez, Jacqueline A Pongracic, Sachin N Baxi, Mindy Benson, Kathryn Blake, Ronina Covar, Deborah A Gentile, Elliot Israel, Jerry A Krishnan, Harsha V Kumar, Jason E Lang, Stephen C Lazarus, John J Lima, Dayna Long, Ngoc Ly, Jyothi Marbin, James N Moy, Ross E Myers, J Tod Olin, Hengameh H Raissy, Rachel G Robison, Kristie Ross, Christine A Sorkness, Robert F Lemanske
Background Asthma exacerbations occur frequently despite the regular use of asthma-controller therapies, such as inhaled glucocorticoids. Clinicians commonly increase the doses of inhaled glucocorticoids at early signs of loss of asthma control. However, data on the safety and efficacy of this strategy in children are limited. Methods We studied 254 children, 5 to 11 years of age, who had mild-to-moderate persistent asthma and had had at least one asthma exacerbation treated with systemic glucocorticoids in the previous year...
March 3, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29499614/use-of-functional-respiratory-imaging-to-characterize-the-effect-of-inhalation-profile-and-particle-size-on-lung-deposition-of-inhaled-corticosteroid-long-acting-%C3%AE-2-agonists-delivered-via-a-pressurized-metered-dose-inhaler
#19
Cedric Van Holsbeke, Jan De Backer, Wim Vos, Jonathan Marshall
BACKGROUND: Functional respiratory imaging (FRI) uses three-dimensional models of human lungs and computational fluid dynamics to simulate functional changes within airways and predict the deposition of inhaled drugs. This study used FRI to model the effects of different patient inhalation and drug formulation factors on lung deposition of an inhaled corticosteroid/long-acting β2 -agonist (ICS/LABA) combination, administered by a pressurized metered-dose inhaler. METHODS: Three-dimensional models of the lungs of six patients with asthma (mean forced expiratory volume in 1 s, 83%), treated with an ICS/LABA, were included...
January 2018: Therapeutic Advances in Respiratory Disease
https://www.readbyqxmd.com/read/29493402/pharmacokinetics-of-salmeterol-and-fluticasone-propionate-delivered-in-combination-via-easyhaler-and-diskus-dry-powder-inhalers-in-healthy-subjects
#20
Merja Kirjavainen, Leena Mattila, Mikko Vahteristo, Jani Korhonen, Satu Lähelmä
BACKGROUND: Easyhaler® dry powder inhaler (DPI) containing salmeterol and fluticasone propionate was developed for the treatment of asthma and chronic obstructive pulmonary disease. Three different Salmeterol/fluticasone Easyhaler test products (Orion Pharma, Finland) were compared against the reference product Seretide® Diskus® DPI (GlaxoSmithKline, United Kingdom) to study whether any of the test products are bioequivalent with the reference. METHODS: Open and randomized pharmacokinetic four-period crossover study on 65 healthy volunteers was performed in a single center to compare the lung deposition and total systemic exposure of salmeterol and fluticasone propionate after administration of single doses (two inhalations of 50/500 μg/inhalation strength) in fasting conditions...
March 1, 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
keyword
keyword
30179
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"